Table 1.

Select agents with reported risk of drug-associated acute interstitial nephritis (1,2,4,10)

Drug Type/ClassSelect Agents
Antimicrobials
β-Lactam antibacterialsPenicillins (e.g., methicillin, nafcillin, amoxicillin)
Cephalosporins
 Other antimicrobialsSulfonamides (e.g., sulfamethoxazole/trimethoprim)
Rifampin
Fluoroquinolones (e.g., ciprofloxacin)
Vancomycin
Acyclovir
Antiretrovirals (e.g., abacavir, indinavir)
Anti-inflammatoryNSAIDs (e.g., ibuprofen, nabumetone)
COX-2 inhibitors (e.g., celecoxib)
5-ASA derivatives (e.g., sulfasalazine, mesalamine)
Acid-suppressive therapyPPIs (e.g., omeprazole, lansoprazole)
Immune checkpoint inhibitorsAnti-PD1 antibody (e.g., pembrolizumab, nivolumab)
Anti-PD-L1 antibody (e.g., durvalumab)
Anti-CTLA-4 antibody (e.g., ipilimumab)
AnticonvulsantsPhenytoin
Carbamazepine
Phenobarbital
OthersAllopurinol
Furosemide
  • NSAIDs, nonsteroidal anti-inflammatory drugs; COX-2 inhibitors, cyclooxygenase-2 inhibitors; 5-ASA, 5-aminosalicylic acid derivatives; PPI, proton-pump inhibitor; anti-PD1 antibody, anti–programmed cell death-1 (PD-1) antibody; anti-PD-L1, anti–programmed cell death ligand-1; anti-CTLA-4 antibody, anti–cytotoxic T lymphocyte-associated antigen 4.